Quarterly report pursuant to Section 13 or 15(d)

Grant and Licensing Revenues (Details)

v3.10.0.1
Grant and Licensing Revenues (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Jun. 30, 2016
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Deferred Revenue Arrangement [Line Items]            
Revenue   $ 1,840,009 $ 470,823 $ 3,735,713 $ 906,313  
Deferred revenue, current   3,090,675   3,090,675   $ 6,826,388
Deferred revenue, noncurrent   200,000   200,000   $ 200,000
Pelican Therapeutics, Inc. [Member]            
Deferred Revenue Arrangement [Line Items]            
Revenue       15,200,000    
Grant Revenue [Member]            
Deferred Revenue Arrangement [Line Items]            
Revenue   $ 1,800,000 500,000 3,700,000 900,000  
Grant Revenue [Member] | In-process R&D [Member]            
Deferred Revenue Arrangement [Line Items]            
Revenue     $ 20,000   $ 20,000  
Grant Revenue [Member] | Pelican Therapeutics, Inc. [Member]            
Deferred Revenue Arrangement [Line Items]            
Revenue $ 15,200,000     $ 3,700,000